Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Vanda Pharmaceuticals announces initiation of ODYSSEY study of tradipitant » 13:42
04/02/20
04/02
13:42
04/02/20
13:42
VNDA

Vanda Pharmaceuticals

$9.78 /

+0.13 (+1.35%)

Vanda Pharmaceuticals…

Vanda Pharmaceuticals announced the initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients with COVID-19. The novel SARS-CoV-2 coronavirus is associated with a lower respiratory tract inflammation that often progresses to Acute Respiratory Distress Syndrome requiring mechanical ventilation. Vanda has received FDA permission to proceed with the study for the treatment and prevention of pneumonia associated with COVID-19. ODYSSEY, which will begin enrolling patients this month, is a Phase III double-blind placebo-controlled trial to investigate the efficacy and safety of tradipitant, a neurokinin-1 receptor antagonist, given orally twice daily to treat inflammatory lung injury associated with severe COVID-19 infection. The study will randomize approximately 300 patients aged 18-90 with severe COVID-19 infection who are suffering from pneumonia. The study will begin at New York area hospitals and will enroll hospitalized patients with COVID-19 ARDS. A recent study in Wuhan, China found that 41.8% of 201 COVID-19 hospitalized patients developed ARDS, and, among these patients, 52.4% died1, underscoring the high rate of mortality in this population. Tradipitant is currently in clinical trials for the treatment of a variety of indications, including atopic dermatitis, gastroparesis and motion sickness. In the ODYSSEY study, tradipitant will be administered in addition to the standard of care, at dosing levels previously tested and generally shown to be well tolerated. Tradipitant targets the neurokinin-1 receptor, which is coded by the TACR1 gene and is the main receptor for substance P, an 11 amino acid neuropeptide with a diverse set of functions. It has been shown that the substance P neurokinin-1 receptor system is involved in the neuroinflammatory processes that leads to significant lung injury following a number of insults, including viral challenges. If the ODYSSEY study demonstrates significant tradipitant effectiveness in treating COVID-19 patients with ARDS, Vanda will work with the FDA in an effort to ensure that this therapy is made available to patients in an expedited manner.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Downgrade
Fly Intel: Top five analyst downgrades » 10:20
03/16/20
03/16
10:20
03/16/20
10:20
UFS

Domtar

$25.50 /

-1.85 (-6.76%)

, HOG

Harley-Davidson

$20.44 /

-3.23 (-13.65%)

, AAL

American Airlines

$12.04 /

-2.25 (-15.75%)

, ALK

Alaska Air

$29.50 /

-8.435 (-22.24%)

, VNDA

Vanda Pharmaceuticals

$9.10 /

-1.14 (-11.13%)

, T

AT&T

$31.10 /

-3.365 (-9.76%)

, CMCSA

Comcast

$35.75 /

-3.69 (-9.36%)

, CMCSK

Comcast

$0.00 /

+ (+0.00%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Domtar (UFS) double downgraded to Underperform from Buy at BofA with analyst George Staphos saying he believes the current set of fundamentals in the Packaging and Paper Products space, if they evolve into a recession, will generate a relatively short-lived downturn with a very gradual recovery. 2. Harley-Davidson (HOG) downgraded to Underperform from Sector Perform at RBC Capital with analyst Joseph Spak citing the "highly uncertain demand picture" amid the COVID-19 spread which is exacerbating the company's structural challenges. 3. American Airlines (AAL) downgraded to Neutral from Buy at Goldman Sachs while Alaska Air (ALK) was downgraded to Buy from Conviction Buy. 4. Vanda Pharmaceuticals (VNDA) downgraded to Underperform from Perform at Oppenheimer with analyst Esther Rajavelu citing the company's announcement that Hetlioz sNDA for Smith-Magenis Syndrome is delayed. While management indicates it can resubmit sNDA reasonably quickly without need for additional efficacy studies, she conservatively model SMS launch delay to 2021 year-end/early 2022. 5. AT&T (T) and Comcast (CMCSA, CMCSK) downgraded to Market Perform from Outperform at Raymond James. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Vanda Pharmaceuticals downgraded to Underperform at Oppenheimer on Hetlioz risks » 08:31
03/16/20
03/16
08:31
03/16/20
08:31
VNDA

Vanda Pharmaceuticals

$10.24 /

-0.05 (-0.49%)

As previously reported,…

As previously reported, Oppenheimer analyst Esther Rajavelu downgraded Vanda Pharmaceuticals to Underperform from Perform with a price target of $7, down from $12. The analyst cited the company's announcement that Hetlioz sNDA for Smith-Magenis Syndrome is delayed. While management indicates it can resubmit sNDA reasonably quickly without need for additional efficacy studies, she conservatively model SMS launch delay to 2021 year-end/early 2022. Separately, Rajavelu also lowered her Hetlioz Non-24 revenue estimates beginning in 2023 given ODE for the indication expires on 1/31/2021, and composition-of-matter patent expires in December 2022.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Vanda Pharmaceuticals downgraded to Underperform from Perform at Oppenheimer » 06:12
03/16/20
03/16
06:12
03/16/20
06:12
VNDA

Vanda Pharmaceuticals

$10.24 /

-0.05 (-0.49%)

Oppenheimer analyst…

Oppenheimer analyst Esther Rajavelu downgraded Vanda Pharmaceuticals to Underperform from Perform.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Fly Intel: Top five analyst upgrades » 10:07
03/12/20
03/12
10:07
03/12/20
10:07
SNAP

Snap

$9.86 /

-0.95 (-8.79%)

, HPQ

HP Inc.

$16.73 /

-2.6402 (-13.63%)

, VNDA

Vanda Pharmaceuticals

$10.60 /

+ (+0.00%)

, AMT

American Tower

$208.99 /

-23.72 (-10.19%)

, FISV

Fiserv

$96.31 /

-5.8 (-5.68%)

Catch up on today's…

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Snap (SNAP) was upgraded to Buy from Hold at Deutsche Bank and Argus. 2. HP Inc. (HPQ) upgraded to Overweight from Neutral at JPMorgan with analyst Paul Coster saying investors should take advantage of the market correction to buy an "attractively-valued stock in advance of positive catalysts." 3. Vanda Pharmaceuticals (VNDA) upgraded to Buy from Neutral at Citi with analyst Joel Beatty saying the value of Vanda's two approved drugs, along with its cash, exceeds the company's current market capitalization. 4. American Tower (AMT) upgraded to Buy from Neutral at New Street. 5. Fiserv (FISV) upgraded to Overweight from Neutral at Atlantic Equities with analyst Kunaal Malde saying the stock's absolute and relative valuations have fallen to close to 5-year lows, which he sees creating an attractive entry point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Citi upgrades Vanda to Buy, says value exceeds current market cap » 06:50
03/12/20
03/12
06:50
03/12/20
06:50
VNDA

Vanda Pharmaceuticals

$10.60 /

-0.2 (-1.85%)

Citi analyst Joel Beatty…

Citi analyst Joel Beatty upgraded Vanda Pharmaceuticals to Buy from Neutral with a price target of $14, down from $19. The value of Vanda's two approved drugs, along with its cash, exceeds the company's current market capitalization, Beatty tells investors in a research note. Further, resolving the dispute with FDA, by either agreeing to the agency's requested animal studies or simply discontinuing further development of tradipitant, would immediately move Vanda shares higher, likely by several dollars, adds the analyst. However, Beatty admits that he has little confidence that the company will resolve the dispute with FDA anytime soon.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Barclays to hold a conference » 04:55
03/12/20
03/12
04:55
03/12/20
04:55
ABC

AmerisourceBergen

$84.90 /

-1.21 (-1.41%)

, AMAG

Amag Pharmaceuticals

$6.62 /

-0.64 (-8.82%)

, AZN

AstraZeneca

$44.57 /

-2.32 (-4.95%)

, AVNS

Avanos

$29.00 /

-3.11 (-9.69%)

, BDX

Becton Dickinson

$232.14 /

-5.18 (-2.18%)

, BIO

Bio-Rad

$345.64 /

-21.41 (-5.83%)

, CAH

Cardinal Health

$48.77 /

-0.94 (-1.89%)

, CLVS

Clovis

$6.16 /

-0.105 (-1.68%)

, COO

Cooper Companies

$323.96 /

-10.03 (-3.00%)

, CVS

CVS Health

$61.26 /

-1.36 (-2.17%)

, DGX

Quest Diagnostics

$99.75 /

-6.65 (-6.25%)

, EHTH

eHealth

$126.95 /

-6.99 (-5.22%)

, EXEL

Exelixis

$17.32 /

-1.09 (-5.92%)

, FATE

Fate Therapeutics

$23.79 /

-2.2 (-8.46%)

, FLDM

Fluidigm

$2.62 /

-0.27 (-9.34%)

, FMS

Fresenius Medical

$35.40 /

-2.24 (-5.95%)

, GRTS

Gritstone Oncology

$6.64 /

-0.39 (-5.55%)

, HRC

Hill-Rom

$89.24 /

-0.89 (-0.99%)

, HUM

Humana

$328.50 /

-20.52 (-5.88%)

, IMMU

Immunomedics

$13.38 /

-1.9 (-12.43%)

, IRWD

Ironwood

$10.49 /

-0.96 (-8.38%)

, ITGR

Integer

$79.28 /

-4.07 (-4.88%)

, JAZZ

Jazz Pharmaceuticals

$108.33 /

-4.42 (-3.92%)

, JNJ

Johnson & Johnson

$131.65 /

-10.05 (-7.09%)

, ZIOP

Ziopharm

$2.53 /

-0.24 (-8.68%)

, VNDA

Vanda Pharmaceuticals

$10.60 /

-0.2 (-1.85%)

, QGEN

Qiagen

$41.10 /

-0.33 (-0.80%)

, MRNA

Moderna

$23.61 /

+1.27 (+5.68%)

, MTD

Mettler-Toledo

$661.68 /

-35 (-5.02%)

, MTEM

Molecular Templates

$13.20 /

-1.48 (-10.08%)

, NTRA

Natera

$31.00 /

+0.07 (+0.23%)

, PODD

Insulet

$172.13 /

-8.29 (-4.59%)

, PTCT

PTC Therapeutics

$47.07 /

-4.23 (-8.25%)

Global Healthcare…

Global Healthcare Conference 2020 will be held in Miami on March 10-12.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Vanda Pharmaceuticals upgraded to Buy from Neutral at Citi » 04:52
03/12/20
03/12
04:52
03/12/20
04:52
VNDA

Vanda Pharmaceuticals

$10.60 /

-0.2 (-1.85%)

Citi analyst Joel Beatty…

Citi analyst Joel Beatty upgraded Vanda Pharmaceuticals to Buy from Neutral with a $14 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Barclays to hold a conference » 04:55
03/11/20
03/11
04:55
03/11/20
04:55
ABC

AmerisourceBergen

$86.11 /

+2.8 (+3.36%)

, AMAG

Amag Pharmaceuticals

$7.26 /

+0.05 (+0.69%)

, AZN

AstraZeneca

$46.89 /

+1.62 (+3.58%)

, AVNS

Avanos

$32.11 /

+0.31 (+0.97%)

, BDX

Becton Dickinson

$237.32 /

+6.55 (+2.84%)

, BIO

Bio-Rad

$367.05 /

+15 (+4.26%)

, CAH

Cardinal Health

$49.71 /

+1.72 (+3.58%)

, CLVS

Clovis

$6.27 /

+0.01 (+0.16%)

, COO

Cooper Companies

$333.99 /

+16.38 (+5.16%)

, CVS

CVS Health

$62.62 /

+1.24 (+2.02%)

, DGX

Quest Diagnostics

$106.40 /

-3.43 (-3.12%)

, EHTH

eHealth

$133.94 /

+3.21 (+2.46%)

, EXEL

Exelixis

$18.41 /

+0.66 (+3.72%)

, FATE

Fate Therapeutics

$25.99 /

+1 (+4.00%)

, FLDM

Fluidigm

$2.89 /

+0.16 (+5.86%)

, FMS

Fresenius Medical

$37.64 /

+0.28 (+0.75%)

, GRTS

Gritstone Oncology

$7.03 /

+0.02 (+0.29%)

, HRC

Hill-Rom

$90.13 /

+1.34 (+1.51%)

, HUM

Humana

$349.02 /

+11.84 (+3.51%)

, IMMU

Immunomedics

$15.28 /

+0.21 (+1.39%)

, IRWD

Ironwood

$11.45 /

+0.14 (+1.24%)

, ITGR

Integer

$83.35 /

+3.1 (+3.86%)

, JAZZ

Jazz Pharmaceuticals

$112.75 /

+2.15 (+1.94%)

, JNJ

Johnson & Johnson

$141.70 /

+5.4 (+3.96%)

, ZIOP

Ziopharm

$2.77 /

-0.06 (-2.12%)

, VNDA

Vanda Pharmaceuticals

$10.80 /

+0.9 (+9.09%)

, QGEN

Qiagen

$41.43 /

+0.075 (+0.18%)

, MRNA

Moderna

$22.34 /

-1.95 (-8.03%)

, MTD

Mettler-Toledo

$696.68 /

+25.36 (+3.78%)

, MTEM

Molecular Templates

$14.68 /

-1.09 (-6.91%)

, NTRA

Natera

$30.93 /

-2.43 (-7.28%)

, PODD

Insulet

$180.42 /

+7.3 (+4.22%)

, PTCT

PTC Therapeutics

$51.35 /

+0.14 (+0.27%)

Global Healthcare…

Global Healthcare Conference 2020 will be held in Miami on March 10-12.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Barclays to hold a conference » 08:27
03/10/20
03/10
08:27
03/10/20
08:27
ABC

AmerisourceBergen

$83.31 /

-2.49 (-2.90%)

, AMAG

Amag Pharmaceuticals

$7.21 /

-0.47 (-6.12%)

, AZN

AstraZeneca

$45.27 /

-2.25 (-4.73%)

, AVNS

Avanos

$31.80 /

-0.71 (-2.18%)

, BDX

Becton Dickinson

$232.60 /

-4.81 (-2.03%)

, BIO

Bio-Rad

$352.05 /

-23.16 (-6.17%)

, CAH

Cardinal Health

$47.99 /

-3.22 (-6.29%)

, CLVS

Clovis

$6.26 /

-1.585 (-20.22%)

, COO

Cooper Companies

$317.61 /

-15.52 (-4.66%)

, CVS

CVS Health

$61.38 /

-2.76 (-4.30%)

, DGX

Quest Diagnostics

$109.83 /

-2.17 (-1.94%)

, EHTH

eHealth

$130.56 /

-3.85 (-2.86%)

, EXEL

Exelixis

$17.75 /

-0.88 (-4.72%)

, FATE

Fate Therapeutics

$24.99 /

-4.35 (-14.83%)

, FLDM

Fluidigm

$2.73 /

-0.24 (-8.08%)

, FMS

Fresenius Medical

$37.36 /

-1.82 (-4.65%)

, GRTS

Gritstone Oncology

$7.01 /

-0.84 (-10.70%)

, HRC

Hill-Rom

$88.79 /

-7.16 (-7.46%)

, HUM

Humana

$337.18 /

-29.73 (-8.10%)

, IMMU

Immunomedics

$15.07 /

-1.35 (-8.22%)

, IRWD

Ironwood

$11.31 /

-0.93 (-7.60%)

, ITGR

Integer

$80.25 /

-4.87 (-5.72%)

, JAZZ

Jazz Pharmaceuticals

$110.60 /

-9.17 (-7.66%)

, JNJ

Johnson & Johnson

$136.30 /

-5.83 (-4.10%)

, ZIOP

Ziopharm

$2.83 /

-0.435 (-13.34%)

, VNDA

Vanda Pharmaceuticals

$9.90 /

-0.62 (-5.89%)

, QGEN

Qiagen

$41.36 /

-0.225 (-0.54%)

, MRNA

Moderna

$24.29 /

-5.29 (-17.88%)

, MTD

Mettler-Toledo

$671.32 /

-43.68 (-6.11%)

, MTEM

Molecular Templates

$15.77 /

-1.6 (-9.21%)

, NTRA

Natera

$33.36 /

-4.97 (-12.97%)

, PODD

Insulet

$173.12 /

-6.39 (-3.56%)

, PTCT

PTC Therapeutics

$51.21 /

-3.8 (-6.91%)

Global Healthcare…

Global Healthcare Conference 2020 will be held in Miami on March 10-12.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.